Tumor Biology

, Volume 36, Issue 6, pp 4349–4356 | Cite as

Neoadjuvant chemotherapy followed by radical surgery as an alternative treatment to concurrent chemoradiotherapy for young premenopausal patients with FIGO stage IIB squamous cervical carcinoma

  • ShanShan Yang
  • Ying Gao
  • Jing Sun
  • Bairong Xia
  • TianBo Liu
  • HongXia Zhang
  • Qi Li
  • Min Xiao
  • YunYan ZhangEmail author
Research Article


Concurrent chemoradiotherapy (cCRT) is the standard of care for International Federation of Gynecology and Obstetrics (FIGO) stage IIB squamous cervical carcinoma (SCC). However, an increasing number of young patients with stage IIB SCC are concerned with preserving their ovarian and vaginal functions during treatment. This retrospective study aimed to compare clinical prognosis between young patients with stage IIB SCC treated with neoadjuvant chemotherapy (NACT) followed by radical surgery (RS) and those treated with cCRT. Medical records of 244 premenopausal patients aged <45 years with FIGO stage IIB SCC treated with NACT+RS and cCRT between February 2007 and June 2009 were reviewed. All these patients completed the treatment plan. NACT+RS resulted in recurrence (35.9 versus 41.8 %, P = 0.350), progression-free survival (PFS) rate (log-rank, P = 0.456), and overall survival (OS) rate (log-rank, P = 0.637) comparable to cCRT. Compared with cCRT, NACT+RS did not show a significant statistical difference in clinical prognosis of premenopausal patients with stage IIB SCC. Therefore, NACT+RS may be considered as an alternative treatment for the young patients who are concerned with preserving endocrine function, and this alternative treatment may also be administered when radiotherapy is unavailable.


Cervical cancer Squamous cell carcinoma Neoadjuvant chemotherapy Radical hysterectomy Concurrent chemoradiotherapy Prognosis 



The authors thank all the people and patients who had participated in this study. This work is supported by Health and Family Planning Commission of Heilongjiang Provincial (No. 2014-363) and the National Natural Science Foundation of China (No. 81372786).

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20:72–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  4. 4.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  5. 5.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Mohar A, Frias-Mendivil M. Epidemiology of cervical cancer. Cancer Invest. 2000;18:584–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007;25:2952–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Suprasert P, Srisomboon J, Kasamatsu T. Radical hysterectomy for stage IIb cervical cancer: a review. Int J Gynecol Cancer. 2005;15:995–1001.CrossRefPubMedGoogle Scholar
  9. 9.
    Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P. Early-stage cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer Ther. 2010;10:451–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Friedlander M, Kaye SB, Sullivan A, Atkinson K, Elliott P, Coppleson M, et al. Cervical carcinoma: a drug-responsive tumor—experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol. 1983;16:275–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Lilic V, Lilic G, Filipovic S, Milosevic J, Tasic M, Stojiljkovic M. Modern treatment of invasive carcinoma of the uterine cervix. J Buon. 2009;14:587–92.PubMedGoogle Scholar
  13. 13.
    Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V, et al. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: evaluation of toxicity and outcome measures. Acta Oncol. 2013;52:166–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007;104:64–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Benedetti Panici P, Bellati F, Pastore M, Manci N, Musella A, Pauselli S, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2007;107:S20–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol. 1990;38:486–93.CrossRefPubMedGoogle Scholar
  17. 17.
    Angioli R, Plotti F, Luvero D, Aloisi A, Guzzo F, Capriglione S, et al. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumour Biol. 2014;35:2741–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Maduro JH, Pras E, Willemse PH, de Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev. 2003;29:471–88.CrossRefPubMedGoogle Scholar
  19. 19.
    NCCN (National Comprehensive Cancer Network) clinical practice guidelines in Oncology:cervical cancer (2014.V1)Google Scholar
  20. 20.
    Shen K, Lang JH. Problems and challenges of gynecological oncology. Beijing: People’s Medical Publishing House; 2002.Google Scholar
  21. 21.
    Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cardenas-Rebollo JM, et al. Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma International Federation of Gynecology and Obstetrics stage IB2-IIB. Int J Gynecol Cancer. 2013;23:1647–54.CrossRefPubMedGoogle Scholar
  22. 22.
    McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013;108:2464–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhao EF, Bao L, Li C, Song L, Li YL. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:605–9.PubMedGoogle Scholar
  24. 24.
    Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29:389–99.CrossRefPubMedGoogle Scholar
  25. 25.
    Candelaria M, Chanona-Vilchis J, Cetina L, Flores-Estrada D, Lopez-Graniel C, Gonzalez-Enciso A, et al. Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Surg Oncol. 2006;3:3.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A, Mohar A, Rivera L, Mota A, et al. Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Ann Oncol. 2002;13:1212–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83 Suppl 1:41–78.CrossRefPubMedGoogle Scholar
  28. 28.
    Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S. Radical hysterectomy for FIGO stage IIb cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol. 2009;114:69–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, et al. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127:114–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125:292–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:420–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012;124:92–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, et al. Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection—an analysis with mathematical statistics. Int J Gynecol Cancer. 1993;3:219–25.CrossRefPubMedGoogle Scholar
  34. 34.
    Wang H, Zhu L, Lu W, Xu H, Yu Y, Yang Y. Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. World J Surg Oncol. 2013;11:301.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007;107:310–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • ShanShan Yang
    • 1
  • Ying Gao
    • 2
  • Jing Sun
    • 1
  • Bairong Xia
    • 2
  • TianBo Liu
    • 2
  • HongXia Zhang
    • 3
  • Qi Li
    • 1
  • Min Xiao
    • 4
  • YunYan Zhang
    • 1
    Email author
  1. 1.Department of Gynecological RadiotherapyThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of GynecologyThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of Medical ImageologyThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  4. 4.Department of Breast SurgeryThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations